Brief: Adicet Reports Third Quarter 2022 Results
Nov 8 (Reuters) - Adicet Bio Inc ACET.O :
* ADICET REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND
PROVIDES
BUSINESS UPDATES
* $282.7 MILLION IN CASH AND CASH EQUIVALENTS AS OF
SEPTEMBER 30,
2022; CASH RUNWAY INTO FIRST HALF OF 2025
* QTRLY NET LOSS OF $0.53 PER BASIC AND DILUTED SHARE
* Q3 EARNINGS PER SHARE VIEW $-0.53 -- REFINITIV IBES DATA
Source text for Eikon: ID:nBw3kDfRda
Further company coverage: ACET.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ADICET Bio
See all newsNASDAQ RESUMED AT 09:35 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:30 AM
Brief: Adicet Bio Announces Positive Safety And Efficacy Data From Prula-Cel (Formerly Adi-001) Study In Patients With Systemic Lupus Erythematosus With Or Without Lupus Nephritis
Brief: Adicet Bio Announces FDA Clearance Of Ind Application For Adi-212
Adicet Bio, Inc. Reports Results For The Quarter Ended June 30: Earnings Summary